Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Protein Profile of Multiple Myeloma-Derived Extracellular Vesicles for the Discovery of Novel Myeloma-Related Biomarkers.

Cancer science·2026
Same author

Rethinking On-Target Off-Tumor Toxicity as a Hematopoietic Continuum.

European journal of haematology·2026
Same author

Mechanisms of post-transplant AML relapse and therapeutic implications.

Bone marrow transplantation·2026
Same author

Ferroptosis in Lymphoproliferative Disorders.

Cells·2026
Same author

Bridging Randomized Trial Efficacy and Real-World Effectiveness in Multiple Myeloma: Integrating Clinical Trials and Real-World Evidence for Individualized Care.

European journal of haematology·2026
Same author

Multiple Myeloma and the Illusion of the Evidence Pyramid.

European journal of haematology·2026

相关实验视频

Updated: Jul 19, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.1K

在多发性髓瘤中使用Selinexor.

Enrica Antonia Martino1, Ernesto Vigna1, Antonella Bruzzese1

  • 1Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.

Expert opinion on pharmacotherapy
|March 19, 2024
PubMed
概括

作为XPO1抑制剂的Selinexor在复发性/耐药性多发性骨髓瘤 (RRMM) 中表现有前途. 临床试验证明了其在组合疗法中的有效性,改善了具有挑战性疾病的患者的响应率和无进展生存率.

关键词:
在 MM MM MM MM 里面.这就是Selinexor.一个XPO1一个XPO1一个XPO1治疗疗法治疗疗法治疗疗法

更多相关视频

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.4K
Preparation of Cytoplasmic and Nuclear Long RNAs from Primary and Cultured Cells
06:29

Preparation of Cytoplasmic and Nuclear Long RNAs from Primary and Cultured Cells

Published on: April 7, 2023

4.9K

相关实验视频

Last Updated: Jul 19, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.1K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.4K
Preparation of Cytoplasmic and Nuclear Long RNAs from Primary and Cultured Cells
06:29

Preparation of Cytoplasmic and Nuclear Long RNAs from Primary and Cultured Cells

Published on: April 7, 2023

4.9K

科学领域:

  • 在瘤学瘤学.
  • 血液学 血液学 血液学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 复发性/耐药性多发性骨髓瘤 (RRMM) 存在重大治疗挑战.
  • 选择性抑制素出口因1 (XPO1) 的Selinexor是一种新兴的治疗选择.

研究的目的:

  • 审查selinexor在多发性骨髓瘤 (MM) 患者的临床疗效和安全性.
  • 探索selinexor在各种组合疗法和患者群体中的作用.

主要方法:

  • 对临床试验的审查,包括STORM和BOSTON.
  • 分析现实世界的证据和正在进行的调查.

主要成果:

  • 在组合治疗方案 (XKd,XRd,XPd) 中,Selinexor表现出显著的整体应答率 (ORR) 和延长的无进展生存期 (mPFS).
  • 在三级耐火和高风险MM患者中观察到有效性,包括那些患有外骨髓性疾病的患者.

结论:

  • 塞利尼克索尔是RRMM多药策略中的通用和关键成分.
  • 精心管理耐药机制和不良事件对于最佳结果至关重要.